利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

28 条记录 (耗时 0.017 秒)

    COMPOSITION FOR THE TREATMENT OF OSTEOARTHRITIS
    3.
    发明申请
    COMPOSITION FOR THE TREATMENT OF OSTEOARTHRITIS 审中-公开

    公开(公告)号：US20200061088A1

    公开(公告)日：2020-02-27

    申请号：US16467207

    申请日：2017-12-06

    申请人： ABIOGEN PHARMA S.P.A.

    发明人： Fabio Neggiani ,  Silvia Trasciatti

    IPC分类号： A61K31/663 ,  A61K9/00 ,  A61K9/08 ,  A61K47/02 ,  A61P19/02

    摘要： The present invention relates to a composition for use in the treatment of osteoarthritis (OA), wherein said composition comprises from 5 to 40 mg of sodium chlodronate, or an equivalent amount of chlodronic acid, or other pharmaceutically acceptable salts thereof, and wherein said composition is administered intra-articularly in a unitary dosage form once monthly, once biweekly or once weekly. Single-dose medicaments and kits comprising them are also described.

    XIBORNOL FOR USE IN THE TREATMENT OF ACNE VULGARIS
    8.
    发明申请
    XIBORNOL FOR USE IN THE TREATMENT OF ACNE VULGARIS 审中-公开

    公开(公告)号：US20200155478A1

    公开(公告)日：2020-05-21

    申请号：US16616570

    申请日：2018-05-30

    申请人： ABIOGEN PHARMA S.P.A.

    发明人： Silvia Trasciatti

    IPC分类号： A61K31/05 ,  A61K8/34

    摘要： The use of xibornol as an active agent in the treatment of Acne vulgaris is disclosed, said xibornol having shown a remarkable bacteriostatic and bactericidal action on the bacterium mainly responsible of the onset and worsening of Acne vulgaris, i.e. the bacterium Propionibacterium acnes. Pharmaceutical or cosmetic compositions comprising xibornol and suitable pharmaceutically or cosmetically acceptable excipients, for use in the treatment of Acne vulgaris are also disclosed.

    POLYMORPH OF SODIUM NERIDRONATE AND PREPARATION PROCESS THEREOF
    9.
    发明申请
    POLYMORPH OF SODIUM NERIDRONATE AND PREPARATION PROCESS THEREOF 审中-公开

    公开(公告)号：US20190308999A1

    公开(公告)日：2019-10-10

    申请号：US16379873

    申请日：2019-04-10

    申请人： ABIOGEN PHARMA S.P.A.

    发明人： Laura Dini ,  Fabio Neggiani ,  Barbara Politi ,  Stefano Luca Giaffreda ,  Alex Petrolati ,  Michel Chiarucci ,  Serena Fabbroni ,  Kesheng Zhang ,  Michael Roeder

    IPC分类号： C07F9/38 ,  C07F9/02 ,  A61P19/10 ,  A61P5/20 ,  A61P19/02 ,  A61P3/14 ,  A61P35/04

    摘要： The present invention relates to a novel crystalline hemihydrate polymorph of neridronic acid sodium salt, and a novel process for the preparation thereof comprising the steps of: 1) dissolving solid sodium neridronate in any crystalline form in water, at a temperature in the range from 70 to 90° C., to obtain an aqueous solution of sodium neridronate; 2) adding a solvent selected from the group consisting in ethanol, 1-propanol, and 2-propanol to the aqueous solution obtained from step (1), so that the final water:solvent volume ratio is in the range from 1:0.5 to 1:1, thus obtaining a suspension; 3) placing the suspension obtained from step (2) under mechanical stirring, at a temperature in the range from 60 to 95° C.; 4) recovering the crystalline hemihydrate form F of sodium neridronate formed in the previous step (3). The crystalline hemihydrate form F of sodium neridronate, particularly stable, may be employed in the preparation of solid oral pharmaceutical forms for use in the treatment of musculoskeletal and calcium metabolism disorders.